ChampionsGate Acquisition Corporation Announces Pricing of $65,000,000 Initial Public Offering

AllianceBernstein (AB) named Onur Erzan as its next CEO, effective April 1, 2027. Erzan, currently president, succeeds Seth Bernstein, who retires but remains on AB's board. AB's assets under management are $919 billion, with $169 billion in private wealth. Erzan joined AB in 2021 from McKinsey and has led key initiatives. AB is a subsidiary of Equitable Holdings.

TD Cowen reduced its Paychex (PAYX) price target to $105 from $117, citing lower growth expectations for management solutions. The firm adjusted fiscal 2027 revenue and EPS estimates, while keeping 2028 estimates unchanged. Paychex stock has fallen 12.5% in a week, trading at $101.73. Multiple analysts have revised targets and earnings forecasts, with mixed views on growth prospects.

Amazon plans to invest $3 billion in India's quick commerce sector by 2030, aiming to expand its Amazon Now service. The company targets 1,300 stores by April 2024, focusing on daily essentials and improving inventory management. Amazon's quick commerce business has reached $1 billion in annualized gross sales, according to the company. The sector is expected to grow to $41 billion by 2030, per Datum Intelligence.

KeyBanc downgraded Comcast (CMCSA) to Underweight, setting a $18 price target. The firm cited weakening broadband subscriber numbers, pressure on connectivity earnings, and declining theme park performance. KeyBanc expects broadband net losses to worsen through 2027, with increased competition from rivals' lower-priced 1-gigabit offers. The analyst also doubts Q4 earnings improvement and sees risk to shares.

Fitch Ratings affirmed AutoZone Inc.'s long-term and short-term debt ratings at 'BBB' and 'F2' respectively, with a stable outlook. The ratings reflect AutoZone's strong market position, consistent growth, and stable credit metrics. Fitch expects EBITDAR leverage to remain low, despite potential debt increases for share buybacks. AutoZone's strategic initiatives, including store expansion and international growth, are seen as positive for long-term market share gains.

A jury awarded Nektar Therapeutics $90M in damages after finding Eli Lilly breached a license agreement. Nektar said the verdict is subject to post-trial proceedings and appeals. The dispute involves a collaboration for developing rezpegaldesleukin. Nektar Therapeutics (NASDAQ:NKTR) and Eli Lilly (NYSE:LLY) are involved.